Insmed Incorporated
Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About INSM
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.
INSM Key Statistics
Stock Snapshot
The current Insmed Incorporated(INSM) stock price is $153.00, with a market capitalization of 33.05B. The stock trades at a price-to-earnings (P/E) ratio of -23.95.
On 2026-03-30, Insmed Incorporated(INSM) stock traded between a low of $149.06 and a high of $155.20. Shares are currently priced at $153.00, which is +2.6% above the low and -1.4% below the high.
The Insmed Incorporated(INSM)'s current trading volume is 4.96M, compared to an average daily volume of 3.06M.
In the last year, Insmed Incorporated(INSM) shares hit a 52-week high of $212.75 and a 52-week low of $60.40.
In the last year, Insmed Incorporated(INSM) shares hit a 52-week high of $212.75 and a 52-week low of $60.40.
INSM News
Morgan Stanley upgraded Insmed (INSM) to Overweight from Equal Weight with a price target of $212, up from $166. The firm says its survey suggests Brinsupri pre...
H.C. Wainwright raised the firm’s price target on Insmed (INSM) to $245 from $230 and keeps a Buy rating on the shares. Recently announced positive ENCORE data...
Insmed CEO reveals Japan patient population exceeds US market for lung disease By William Temple Published Mar 25, 10:58AM EDT Quick Read Insmed (INSM) announ...
Analyst ratings
100%
of 21 ratingsMore INSM News
If you are wondering whether Insmed at US$139.14 is priced for opportunity or already reflecting a lot of expectations, the starting point is to get very clear...
TD Cowen raised the firm’s price target on Insmed (INSM) to $243 from $241 and keeps a Buy rating on the shares. The firm updated its model following the releas...
Wells Fargo raised the firm’s price target on Insmed (INSM) to $177 from $175 and keeps an Overweight rating on the shares. The firm thinks the Arikayce top lin...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.